Sagimet Biosciences Inc. SGMT
9.24
0.13
1.43%
as of 25 Sep
- Market cap
- $561.1M
- P/E
- 0.0×
Follow SGMT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
12.76 | 22.18 | 19.74 | 44.31 | |
Current Ratio |
13.06 | 22.82 | 20.34 | 45.02 | |
Net Debt/EBITDA |
8.18 | 10.81 | 8.82 | 15.16 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 1.24 | 0.81 | 0.80 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.31) | (0.37) | (0.26) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.31) | (0.37) | (0.26) | (0.21) | |
Cash per Share |
3.59 | 3.50 | 3.21 | 4.52 | |
Shareholders Equity per Share |
3.67 | 3.44 | 3.15 | 4.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.67 | 3.44 | 3.15 | 4.82 | |
Free Cash Flow |
(10.18) | (11.83) | (8.61) | (11.10) | |
Working Capital |
110.33 | 111.30 | 102.42 | 238.57 | |
Net Current Asset Value |
110.33 | 111.30 | 102.42 | 236.71 | |
EV/EBIT |
— | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
2.70 | 1.37 | 2.76 | 1.53 | |
Average Assets |
151.59 | 138.37 | 126.96 | 200.42 | |
Average Common Equity |
144.97 | 133.59 | 120.73 | 193.16 |
Columns are period end dates